pentamidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
pentamidine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Pentamidine (PMD) is an anti-protozoa drug with potential anticancer activity." | 1.38 | Pentamidine sensitizes chronic myelogenous leukemia K562 cells to TRAIL-induced apoptosis. ( Jiang, J; Liu, XS; Qiu, G, 2012) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Qiu, G | 1 |
Jiang, J | 1 |
Liu, XS | 1 |
Other Studies
1 other study available for pentamidine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Article | Year |
---|---|
Pentamidine sensitizes chronic myelogenous leukemia K562 cells to TRAIL-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cell Survival; Humans; K562 | 2012 |